2020 Annual Meeting | IS3 - Invited Science: Neuromuscular
| 01:00 PM - 01:20 PM | Speaker |
Improving Neuropathy and Mobility in Diabetes: the INMED trial
Lindsay A. Zilliox, MD |
| 01:20 PM - 01:40 PM | Speaker |
Gut Microbiome and its Potential Role in Obesity-Induced Allodynia
|
| 01:40 PM - 02:00 PM | Speaker |
A recessive repeat expansion causes CANVAS and is a common cause of Late-Onset Sensory Ataxia
|
| 02:00 PM - 02:20 PM | Speaker |
Gene Replacement Therapy For CMT1X Neuropathy
|
| 02:20 PM - 02:40 PM | Speaker |
Long-term Safety and Efficacy of Patisiran in Patients with hATTR Amyloidosis: Global OLE Study
Michael J. Polydefkis, MD, FAAN |
| 02:40 PM - 03:00 PM | Speaker |
Targeting a core axonal degeneration program to treat vincristine and bortezomib-induced axonal degeneration
Stefanie Geisler, MD |
| Lindsay A. Zilliox, MD | Dr. Zilliox has nothing to disclose. |
| No disclosure on file | |
| Michael J. Polydefkis, MD, FAAN | Dr. Polydefkis has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alnylam Pharmaceuticals. Dr. Polydefkis has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Akcea. Dr. Polydefkis has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Vertex Pharmaceutical . Dr. Polydefkis has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen-Idec. Dr. Polydefkis has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pfizer. |
| Stefanie Geisler, MD | The institution of Dr. Geisler has received research support from NIH. The institution of Dr. Geisler has received research support from HESI Thrive. The institution of Dr. Geisler has received research support from Foundation for Peripheral Neuropathy. The institution of Dr. Geisler has received research support from Department of Defense. The institution of Dr. Geisler has received research support from Alnylam Therapeutics. Dr. Geisler has received intellectual property interests from a discovery or technology relating to health care. An immediate family member of Dr. Geisler has received publishing royalties from a publication relating to health care. |
| Ahmet Hoke, MD, PhD, FAAN | Dr. Hoke has received personal compensation in the range of $50,000-$99,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Disarm. Dr. Hoke has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. Dr. Hoke has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Annals of Clinical and Translational Neurology. Dr. Hoke has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Burke and Thomas. Dr. Hoke has received stock or an ownership interest from Axoprotego Therapeutics. The institution of Dr. Hoke has received research support from NIH. The institution of Dr. Hoke has received research support from DOD. The institution of Dr. Hoke has received research support from Dr. Miriam and Sheldon G. Adelson Medical Research Foundation. The institution of Dr. Hoke has received research support from Foundation for Peripheral Neuropathy. Dr. Hoke has received intellectual property interests from a discovery or technology relating to health care. |
| Alejandro Tobon, MD, FAAN | Dr. Tobon has nothing to disclose. |